ArticleParasites & vectors2025
Circulating microRNA signatures for echinococcosis.
Article in Parasites & vectors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Non-coding RNAs in parasitic diseases: a bibliometric analysis of knowledge structure, research hotspots, and future directions.Frontiers in cellular and infection microbiology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundEchinococcosis, a serious zoonotic parasitic disease caused by tapeworms of the genus Echinococcus, is clinically characterized by a long latent period of up to 10 years. An accurate diagnosis is critical for the efficient management and treatment of patients. The aim of this study was to identify robust diagnostic signatures for echinococcosis.
methodsUsing co-immunoprecipitation and RNA sequencing (RNA-seq), we comparatively profiled the Argonaute 2-binding microRNAs (abmiRNAs) in hepatocytes of Echinococcus multilocularis-infected mice. Using receiver operating characteristic curve (ROC) analysis, we established quantitative PCR (qPCR) assays based on circulating liver-specific abmiRNAs and their combinations, and further validated these assays using blinded serum samples from infected mice and patients.
resultsThree abmiRNAs were identified as being predominantly expressed in the liver: miR-192-5p, miR-122-5p and miR-21a-5p. While these three abmiRNAs are upregulated in liver cancer and hepatitis virus infections, we found that all circulating abmiRNAs were significantly and gradually downregulated as the Emultilocularis infection progressed; however, they were rapidly upregulated following anthelmintic treatment. The qPCR assays targeting these circulating abmiRNAs and their combinations showed high sensitivity and specificity. Individual circulating abmiRNAs and their combinations accurately distinguished infections in both mice (n = 50) and humans (n = 117), with the combination of miR-192-5p and miR-122-5p being particularly effective in distinguishing infections. This combination was also sensitive to anthelmintic treatment.
conclusionsThese results suggest that circulating miR-192-5p and miR-122-5p are serum signatures for the diagnosis and prognostic management of echinococcosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.